MedTrace Logo

Drug Use Investigation for IMIGRAN Tablet

NCT01376141 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3571

Last updated 2017-05-22

No results posted yet for this study

Summary

The study is designed to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy of sumatriptan tablet, and to discuss the need of special investigation and postmarketing clinical study.

A special focus was placed on the investigation of occurrence of "ischaemic heart disease-like events including arrhythmia, angina pectoris, and myocardial infarction" in the present study.

Conditions

  • Migraine Disorders

Interventions

DRUG

Sumatriptan

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2005-02-28
Completion
2005-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01376141 on ClinicalTrials.gov